Trial abstract · §3
SEMAX-RU-STROKE — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Functional outcome after ischaemic stroke | As above. The Institute grades all claims for this compound very low certainty for absence of retrievable evidence, which is distinct from evidence of absence | Not rated |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Semax from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nasal irritation | — | — | Reported with intranasal use |
| No serious adverse events reported | — | — | In the available Russian studies, though adverse-event ascertainment methodology is not described to a standard permitting assessment |
Compound Evidence Institute · CEI-TR-0125/3 · https://compoundevidence.com/trials/semax-ru-stroke/results/ · retrieved 30 July 2026